4//SEC Filing
Downs Christopher 4
Accession 0001683168-23-002829
CIK 0001729427other
Filed
Apr 30, 8:00 PM ET
Accepted
May 1, 6:59 PM ET
Size
7.7 KB
Accession
0001683168-23-002829
Insider Transaction Report
Form 4
Downs Christopher
Chief Financial Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2023-04-28−521→ 28,248 total→ Common Stock (521 underlying) - Exercise/Conversion
Common Stock
2023-04-28+521→ 9,772 total
Footnotes (2)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]On April 28, 2022, the reporting person received 8,335 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors.
Documents
Issuer
CNS Pharmaceuticals, Inc.
CIK 0001729427
Entity typeother
Related Parties
1- filerCIK 0001705978
Filing Metadata
- Form type
- 4
- Filed
- Apr 30, 8:00 PM ET
- Accepted
- May 1, 6:59 PM ET
- Size
- 7.7 KB